Doctor’s pharma links raise fears of bias on opioid panel - The Globe and Mail. Officials overseeing new national standards for prescribing opioids did not honour a pledge to exclude medical experts who receive income from drug companies from voting on the measures.
Sol Stern, a family doctor in Oakville, Ont., and one of 13 panel members who voted on the standards, has been a paid speaker and advisory board member for drug companies, including the pharmaceutical giant whose pain pill triggered Canada’s deadly opioid epidemic, according to his declaration form posted online last week. Jason Busse, an associate professor at McMaster University’s department of anesthesia and co-lead of the group that drafted the standards, said the group made an exception for Dr. Stern because his industry-sponsored talks represented a “balanced approach” to opioids. Dr. American Health Care's "Original Sin" - HealthCommentary : HealthCommentary. Posted on | May 17, 2017 | 2 Comments Mike Magee As a young surgeon in rural New England, serving farmers and mountain people on the Massachusetts/Vermont border, my growing interest in health management was fueled by two luminaries – one 90 miles to the north and the other 90 miles to the east.
One was fast at work mining Medicare databases to expose high geographic variability in diagnosis and treatment suggesting both inequality and inequity. The other was a student of all things Deming, a land where there were no bad employees, just bad processes. Both believed that the answer to healing an obviously unwell US health care system was data, analysis and systematic reform. What Do Patients Think About Physicians’ Conflicts of Interest? Medical conflicts of interest were perfectly evident to patients long before anyone took an active interest in revealing them.
These conflicts have been obvious from the moment the first physician accepted the first coin to enter the first plague-stricken home and do what little could be done. Billions wasted on drug spending in Canada, exclusive research shows - Health. Canada wasted $15 billion over the last five years on highly priced prescription drugs, in part because of questionable drug company sales tactics, according to exclusive research and a hidden camera investigation by the fifth estate.
John Herbert, a director for Express Scripts Canada, says money can be saved by Canadians and their employers choosing to take advantage of 'lower-cost, clinically effective medications.' (Express Scripts Canada ) The research conducted for the fifth estate by health benefits company Express Scripts Canada shows employer-funded private insurance plans in Canada wasted more than $3 billion per year between 2011 and 2015 by covering the cost of expensive drugs that have cheaper options, as well as paying for unnecessary dispensing fees. That's nearly 20 per cent of the $81 billion spent on drugs over those five years by private insurance companies in Canada.
Dr. Pharmaceutical Industry–Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. Importance The association between industry payments to physicians and prescribing rates of the brand-name medications that are being promoted is controversial.
In the United States, industry payment data and Medicare prescribing records recently became publicly available. It’s time to address the overtreatment of thyroid cancer. In 1994, my entire thyroid was removed because of a single, small tumour.
The Paradox of Disclosure. Photo A POPULAR remedy for a conflict of interest is disclosure — informing the buyer (or the patient, etc.) of the potential bias of the seller (or the doctor, etc.).
Rx pizza: 1 free meal can sway doctor prescribing. CHICAGO - As little as one free meal from a drug company can influence which medicines doctors prescribe for Medicare patients, according to a study using Medicare records and recently released data from the health care law's Open Payments program.
The study highlights the subtle ways doctors may feel inclined to prescribe a drug after receiving just a small gift, even if the drug is more costly for patients and their insurance plans, the study authors said. In a typical scenario, drug companies sometimes sponsor meals served during medical conferences and their sales reps may offer drug information and free samples to doctors waiting in line for food. Dr. Justifying conflicts of interest in medical journals: a very bad idea. Robert Steinbrook, professor adjunct of internal medicine1, Jerome P Kassirer, distinguished professor2, Marcia Angell, senior lecturer on social medicine3Author affiliationsCorrespondence to: firstname.lastname@example.org A series of articles in the New England Journal of Medicine has questioned whether the conflict of interest movement has gone too far in its campaign to stop the drug industry influencing the medical profession.
Here, three former senior NEJM editors respond with dismay A seriously flawed and inflammatory attack on conflict of interest policies and regulations appeared recently in a most unexpected location: the venerable and trusted New England Journal of Medicine (NEJM). Physicians and the public rely on journals as unbiased and independent sources of information and to provide leadership to improve trust in medicine and the medical literature. Straw men Editorial responsibility. BMJ editor Fiona Godlee takes on corruption in science - Health. It's unusual to watch one of the world's most powerful editors in scientific publishing play with a marionette puppet.
But Dr. F.D.A. Asks If Faulty Blood Monitor Tainted Xarelto Approval. Shire, Maker of Binge-Eating Drug Vyvanse, First Marketed the Disease. Photo. The problem of expert fallacy in cancer screening guidelines. The American Cancer Society (ACS), an advocacy organization that has fairly recently (and very positively) taken a more appropriate, evidence-based approach to cancer screening, recently revised its mammography recommendations. While it still recommends more mammograms than the U.S. Doing More vs Doing Good: Aligning Our Ethical Principles From the Personal to the Societal. This Viewpoint explores the topic of overtreatment and its ethical and financial effects on health care and contribution to waste in the health care system. Health care in the United States is in a state of significant transition. With health care expenditures approaching $3 trillion, substantial attention has been focused on waste in the system. Backlash against “pinkwashing” of breast cancer awareness campaigns.
Big business is keen to jump on the breast cancer awareness bandwagon but do its messages around screening do more harm than good? Meg Carter reports Each October, breast cancer awareness month provides an annual focus for pink ribbon themed campaigns—many of which are backed by commercial partners eager to be seen to support a worthy cause. The pink ribbon began as a grassroots movement, with survivors wearing ribbons to show solidarity with each other.1 But it was quickly appropriated by commercial businesses such as Estée Lauder and breast cancer organisations, led by the US based Susan G Komen Foundation, to show support ranging from financial donations to goodwill.2 The amount of cash raised with commercial backing can be substantial.
Contributors to primary care guidelines. Last Week Tonight with John Oliver: Marketing to Doctors (HBO) Why the Ethics of Parsimonious Medicine Is Not the Ethics of RationingThe Ethics of Parsimonious Medicine. The ethics of rationing health care resources has been debated for decades. Web of industry, advocacy, and academia in the management of osteoporosis. Whistle-blower: How doctor uncovered nightmare. Doctors, Money, and Conflicts of Interest. Quand l’hépatologie s’enhardit à propos de l’efficacité des nouveaux médicaments de l’hépatite C, mais reste muette sur les lourds liens d’intérêts qui l’unissent aux industriels. Alerté par les propos démesurés de quelques leaders d’opinion en hépatologie au sujet du bénéfice procuré aux patients par les nouveaux antiviraux dans l’hépatite C chronique, je commence par collecter leurs liens d’intérêts avec les firmes pharmaceutiques présentes sur ce marché juteux, dominé par l’américain GILEAD Sciences et son SOVALDI®.
En tirant sur la pelote de laine, je découvre la construction sous son emprise à l’occasion de l’élaboration du rapport ministériel « DHUMEAUX », d’une « redoutable machine de guerre » à dilapider l’argent public pour maximiser leurs profits. L’absence totale de gestion par les pouvoirs publics des lourds conflits d’intérêts de ces hépatologues a conduit au désastre financier que l’on connaît (1 milliard d’euros en 2014) sans que l’on sache vraiment quel en sera le bénéfice pour les patients. Introduction Mais, la maladie doit-elle se confondre avec l’agent pathogène ? Plan de l’article Les propos excessifs et prématurés tenus par les hépatologues. Centers for Disease Control and Prevention: protecting the private good?